Ozempic and Chronic Kidney Disease: FLOW Trial and Kidney Outcomes

Research brief

What FLOW changed in the semaglutide kidney evidence base

FLOW Trial at a Glance

The primary FLOW publication in the New England Journal of Medicine is the key source for interpreting the trial's population, endpoint definitions and outcomes. NEJM: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Why FLOW matters

Before FLOW, semaglutide and other GLP-1 receptor agonists had already produced kidney-related signals in cardiovascular and diabetes trials, including effects on albuminuria and composite renal endpoints. But those studies were not designed primarily as dedicated kidney-outcomes trials. FLOW changed the strength of the evidence because kidney disease progression was central to the trial design.

This distinction matters for search queries such as “Ozempic kidney benefits” or “semaglutide kidney disease.” A reduction in albuminuria is not the same thing as proving fewer major kidney events. FLOW provides stronger clinical evidence because the trial directly tested clinically important kidney and cardiovascular outcomes in a CKD population.

What FLOW establishes

• Semaglutide has dedicated randomized kidney-outcome evidence in adults with type 2 diabetes and CKD.
• The trial showed a lower risk of the primary composite kidney and cardiovascular outcome versus placebo.
• The study assessed kidney-function decline and cardiovascular outcomes in addition to the primary composite.
• The evidence supports semaglutide as part of a broader kidney-risk-reduction strategy in the population studied.
• The findings connect kidney and cardiovascular risk, consistent with the modern CKM framework.

What FLOW does not establish

• It does not prove the same benefit in every form of chronic kidney disease.
• It does not automatically establish equivalent benefit in people with CKD who do not have type 2 diabetes.
• It does not mean semaglutide replaces RAS inhibitors, SGLT2 inhibitors or other established CKD therapies.
• It does not prove that every GLP-1 drug has identical kidney-outcome evidence.
• It does not turn a population-level trial result into an individualized treatment recommendation.

Why the population boundary is essential

FLOW specifically enrolled adults with both type 2 diabetes and chronic kidney disease. That is a clinically important population because diabetes is one of the major causes of CKD and because kidney disease substantially increases cardiovascular risk.

But CKD is not one disease. Non-diabetic CKD can result from glomerular disorders, inherited kidney disease, vascular disease, autoimmune conditions, obstructive disease and other causes. A positive trial in diabetic CKD can generate hypotheses about broader kidney protection, but it cannot by itself establish clinical benefit in every other CKD population.

Albuminuria, eGFR and harder kidney outcomes

Kidney research often moves from early markers toward harder outcomes. Albuminuria reflects leakage of albumin into urine and is associated with both kidney and cardiovascular risk. eGFR estimates kidney filtration and can be used to track the rate of kidney-function decline over time.

Harder outcomes include sustained large reductions in kidney function, kidney failure, dialysis, transplantation or kidney-related death. Composite endpoints combine several of these clinically important events so that trials can assess progression across a spectrum of severity.

FLOW's value lies in moving beyond a single biomarker. It evaluated a clinically meaningful composite in a population at high risk of kidney progression and cardiovascular events.

How semaglutide fits with SGLT2 inhibitors and RAS inhibition

Modern CKD care is layered. Current CKM and diabetes guidance gives important foundational roles to renin-angiotensin-system inhibition and SGLT2 inhibitors in appropriate people with diabetic CKD. Finerenone may also be added for selected patients with persistent albuminuria.

Semaglutide should therefore not be framed as a replacement for those therapies. The more accurate interpretation is that GLP-1-based therapy can contribute additional metabolic, cardiovascular and kidney benefit when supported by the patient's risk profile and tolerated background treatment.

Why kidney and cardiovascular outcomes are combined

CKD substantially raises cardiovascular risk, and cardiovascular disease is a major cause of morbidity and mortality in people with kidney disease. For that reason, modern kidney-outcomes trials frequently include cardiovascular death within composite endpoints.

This is also why the 2026 cardiovascular-kidney-metabolic framework is useful. It reflects the reality that progression in one organ system can affect outcomes in another. A kidney trial may therefore generate clinically important cardiovascular information without becoming primarily a cardiovascular trial.

Ozempic, semaglutide and brand-specific interpretation

Ozempic contains semaglutide, but evidence should still be described carefully by product, dose, trial and regulatory context. Search users often move between the molecule name and the brand name as though they are interchangeable. Scientifically, the active ingredient connects the evidence base, but regulatory claims still depend on the approved product labeling and studied use.

That is why GLP1Scientist links this page both to the Ozempic hub and the broader semaglutide hub.

FLOW and the evidence ladder

What readers should not infer from the trial

A common mistake is to transform a positive kidney trial into a universal statement such as “Ozempic prevents kidney failure.” The evidence does not justify that simplification. Clinical trials estimate average effects within defined populations and endpoint structures. Individual outcomes vary, and CKD progression is affected by disease cause, baseline kidney function, albuminuria, blood pressure, diabetes control, cardiovascular disease and background therapy.

Another mistake is to assume that kidney benefits from semaglutide automatically apply identically to every GLP-1 receptor agonist. Class effects can be biologically plausible, but clinical evidence still needs to be demonstrated for each drug and outcome.

Population Boundary Box

Key FLOW and CKD sources

• NEJM: FLOW trial
• FDA: Ozempic prescribing information
• ADA Standards of Care 2026: Chronic Kidney Disease and Risk Management
• 2026 AHA/ACC/ADA/ASN CKM Guideline